The FRAIL AF Study

Multiple studies highlight the benefits of direct oral anticoagulants (DOACS) with lower incidence of side effects and non-inferiority to warfarin. Join host, Geoff Wall, and guest, Mathew Boyd, as they discuss the FRAILE AF study and whether warfarin may be the best bet in older adults. The GameChanger:DOACs are recommended by nearly all relevant major medical guidelines as the anticoagulant of choice in atrial fibrillation. A new study has found that in frail elderly patients, warfarin may be associated with fewer bleeding episodes. HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthGuestMathew Boyd, PharmDClinical PharmacistUnity Point ReferenceJoosten LPT, van Doorn S, van de Ven PM,et al. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066485. Epub ahead of print. PMID: 37634130.https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the design and results of the FRAIL AF study 2. Apply the results of the Groningen Frailty Index to a specific patient 0.05 CEU/0.5 HrUAN: 0107-0000-23-302-H01-PInitial release date: 9/25/2023Expiration date: 9/25/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram